Although clozapine-induced granulocytopenia (CIG) is less severe than clozapine-induced agranulocytosis (CIA), and some patients with CIG may not go on to develop serious complications, clozapine is discontinued in cases of both CIA and CIG. Understanding the pathogenic mechanisms of CIA/CIG could provide better management of clozapine therapy. Recently, as a mechanistic insight into adaptive immune systems, European groups reported clozapine-specific proliferative responses and clozapine-specific T cells using blood taken from patients with CIA and/or CIG.
Aims:
The aims of our study are to support this mechanistic evidence and to investigate the difference in the lymphocyte response to clozapine between patients with CIG and those with CIA.
Methods:
Lymphocyte stimulation tests (LSTs) were conducted using CD25-positive cell-depleted peripheral blood-derived mononuclear cells (PBMCs) isolated from blood of four Japanese patients with CIA, four patients with CIG, and nine clozapine-tolerant subjects.
Results:
Three of four patients with CIA and one of four patients with CIG showed proliferative responses to clozapine with a stimulation index of greater than 2. In contrast, none of the nine clozapine-tolerant subjects showed any response to clozapine. Olanzapine did not stimulate PBMCs of patients with CIA, patients with CIG, or clozapine-tolerant subjects.
Conclusions:
Clozapine- and CIA-specific lymphocyte reactions in a Japanese population provided supportive evidence that the pathogenesis of CIA is based on adaptive immune reactions. In addition, patients with CIG who show a positive response to an LST may at the very least not be chosen for clozapine-rechallenge and further prospective studies are desirable to verify this hypothesis.
AlvirJMLiebermanJASaffermanAZ, et al (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med329: 162–167.
2.
AndrèsEMourot-CottetR (2017) Non-chemotherapy drug-induced neutropenia – An update. Expert Opin Drug Saf16: 1235–1242.
3.
AndrèsEZimmerJAffenbergerS, et al (2006) Idiosyncratic drug-induced agranulocytosis: Update of an old disorder. Eur J Intern Med17: 529–535.
4.
AtkinKKendallFGouldD, et al (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry169: 483–488.
5.
BeelerAEnglerOGerberBO, et al (2006) Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol117: 455–462.
6.
CohenDBogersJPvan DijkD, et al (2012) Beyond white blood cell monitoring: Screening in the initial phase of clozapine therapy. J Clin Psychiatry73: 1307–1312.
7.
CopolovDLBellWRBensonWJ, et al (1998) Clozapine treatment in Australia: A review of haematological monitoring. Med J Aust168: 495–497.
DevarbhaviHRajSAradyaVH, et al (2016) Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology63: 993–999.
10.
DoldMLeuchtS (2014) Pharmacotherapy of treatment-resistant schizophrenia: A clinical perspective. Evid Based Ment Health17: 33–37.
11.
DunkLRAnnanLJAndrewsCD. (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry188: 255–263.
12.
ElsheikhALavergneSNCastrejonJL, et al (2010) Drug antigenicity, immunogenicity, and costimulatory signaling: Evidence for formation of a functional antigen through immune cell metabolism. J Immunol185: 6448–6460.
13.
EssaliAAl-Haj HaasanNLiC, et al (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev2009: Cd000059.
14.
FaulknerLMartinssonKSantoyo-CastelazoA, et al (2012) The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol Sci127: 150–158.
15.
GhaznaviSNakicMRaoP, et al (2008) Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry165: 813–818.
16.
GoldsteinJIJarskogLFHilliardC, et al (2014) Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun5: 4757.
17.
GuestISokolukBMacCrimmonJ, et al (1998) Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology131: 53–65.
18.
HasanAFalkaiPWobrockT, et al (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry13: 318–378.
19.
HathawayDBFrankenburgF. (2019) Diurnal variability in neutrophil counts in clozapine treatment: A case report and review of the literature. J Clin Psychopharmacol39: 506–508.
20.
HummerMKurzMBarnasC, et al (1994) Clozapine-induced transient white blood count disorders. J Clin Psychiatry55: 429–432.
21.
InadaKOshibuchiHIshigookaJ, et al (2018) Analysis of clozapine use and safety by using comprehensive National data from the Japanese clozapine patient monitoring Service. J Clin Psychopharmacol38: 302–306.
22.
JohnstonAUetrechtJ (2015) Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol11: 243–257.
23.
KanoYHiraharaKMitsuyamaY, et al (2007) Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: Dependence on its timing and the type of drug eruption. Allergy62: 1439–1444.
24.
KatoKKawaseAAzukizawaH, et al (2017) Novel interferon-γ enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. J Dermatol Sci86: 222–229.
25.
LeggeSEWaltersJT (2019) Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics20: 279–290.
26.
LewisSWBarnesTRDaviesL, et al (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull32: 715–723.
27.
LeykinIMayerRShinitzkyM (1997) Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology37: 75–86.
28.
LuqueILeyvaLJosé TorresM, et al (2001) In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy56: 611–618.
29.
ManuPSarpalDMuirO, et al (2012) When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res134: 180–186.
30.
MariaVAVictorinoRM (1997) Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut41: 534–540.
31.
MathewsonKALindenmayerJP (2007) Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia. J Clin Psychopharmacol27: 714–715.
32.
MunroJO’SullivanDAndrewsC, et al (1999) Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry175: 576–580.
33.
NgWKennarRUetrechtJ (2014) Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol27: 1104–1108.
34.
NielsenJYoungCIfteniP, et al (2016) Worldwide differences in regulations of clozapine use. CNS Drugs30: 149–161.
35.
NooijenPMCarvalhoFFlanaganRJ (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol26: 112–119.
36.
NyfelerBPichlerWJ (1997) The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy27: 175–181.
37.
OgeseMOJenkinsREMaggsJL, et al (2015) Characterization of peroxidases expressed in human antigen presenting cells and analysis of the covalent binding of Nitroso sulfamethoxazole to Myeloperoxidase. Chem Res Toxicol28: 144–154.
38.
OgeseMOListerAJenkinsRE, et al (2020) Characterization of clozapine-responsive human T cells. J Immunol205: 2375–2390.
39.
OloyedeECasettaCDzahiniO, et al (2021) There is life after the UK Clozapine central non-rechallenge database. Schizophr Bull47: 1088–1098.
40.
PereiraADeanB (2006) Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: A potential in vitro system for the study of agranulocytosis. Biochem Pharmacol72: 783–793.
41.
PhillipsDRezvaniKBainBJ (2000) Exercise induced mobilisation of the marginated granulocyte pool in the investigation of ethnic neutropenia. J Clin Pathol53: 481–483.
42.
PichlerWJNaisbittDJParkBK (2011) Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol127: S74–S81.
43.
PichlerWJTilchJ (2004) The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy59: 809–820.
44.
PirmohamedMParkK (1997) Mechanism of clozapine-induced agranulocytosis: Current status of research and implications for drug development. CNS Drugs7: 139–158.
45.
RapaportMHMcAllisterCGKirchDG, et al (1991) The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiatry29: 715–717.
46.
RegenFHerzogIHahnE, et al (2017) Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol316: 10–16.
47.
SaitoTIkedaMMushirodaT, et al (2016) Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population. Biol Psychiatry80: 636–642.
48.
SandersonJPNaisbittDJFarrellJ, et al (2007) Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol178: 5533–5542.
49.
SrinoulprasertYPichlerWJ (2014) Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells. Int Arch Allergy Immunol163: 198–205.
50.
ToyodaKHataTYamauchiS, et al (2021) A descriptive study of 10-year clozapine use from the nationwide database in Japan. Psychiatry Res297: 113764.
51.
UetrechtJNaisbittDJ (2013) Idiosyncratic adverse drug reactions: Current concepts. Pharmacol Rev65: 779–808.
52.
UsuiTNaisbittDJ (2017) Human leukocyte antigen and idiosyncratic adverse drug reactions. Drug Metab Pharmacokinet32: 21–30.
53.
van der HeidenMDuizendstraABerbersGAM, et al (2017) Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults. Vaccine35: 5581–5588.
54.
WarringtonRJMcPhilips-FeenerSRutherfordWJ (1982) The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy12: 217–222.
55.
WhiskeyETaylorD. (2007) Restarting clozapine after neutropenia: Evaluating the possibilities and practicalities. CNS Drugs21: 25–35.
56.
WilliamsDPPirmohamedMNaisbittDJ, et al (2000) Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol58: 207–216.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
